CoChat
Sign Up
Cited by 25CAR-T cell therapy researchMultiple Myeloma Research and TreatmentsImmunotherapy and Immune Responses

The DOI matches its Crossref record.

Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up

Van De Donk, Niels WCJ, Agha, Mounzer, Cohen, Adam D, Cohen, Yael C, Anguille, Sébastien, Kerre, Tessa, Roeloffzen, Wilfried W.H., Schecter, Jordan M, De Braganca, Kevin C, Jackson, Carolyn C, Varsos, Helen, Mistry, Pankaj, Roccia, Tito, Xu, Xiaoying, Li, Katherine, Zudaire, Enrique, Corsale, Christina, Akram, Muhammad, Geng, Dong, Pacaud, Lida, Sonneveld, Pieter, Zweegman, Sonja·2022·Blood
DOI 10.1182/blood-2022-159169
Open this paper in CoChat — free account

Abstract

Introduction: In cohort B of the multicohort phase 2 CARTITUDE-2 (NCT04133636) study, the efficacy and safety of cilta-cel are being evaluated in patients with multiple myeloma (MM) who had early relapse (≤12 months after autologous stem cell transplant [ASCT] or ≤12 months after start of initial treatment with anti-myeloma therapy). Because progression within 1 year of starting initial therapy is a poor prognostic factor, with overall survival <2 years in these patients, they have functionally high-risk disease and represent an unmet medical need. We present updated clinical results and cytokine analyses. Methods: Eligible patients had MM, received 1 prior line of therapy (proteasome inhibitor and immunomodulatory drug required), had early disease progression (≤12 mo after ASCT or ≤12 mo after start of anti-myeloma therapy for patients who did not undergo ASCT), and were treatment-naive to CAR-T/anti-B-cell maturation antigen (BCMA) therapies. Bridging therapy was allowed between apheresis and CAR-T cell infusion. A single cilta-cel infusion (target dose 0.75×106 CAR+ viable T cells/kg) was given post lymphodepletion. Safety and efficacy were assessed. The primary endpoint was minimal residual disease (MRD) negativity by next generation sequencing at 10-5. Management strategies were implemented to minimize risk of movement/neurocognitive treatment-emergent adverse events (MNTs)/parkinsonism. Pharmacokinetics, CAR-T cell phenotype, and cytokine profiles are also being investi…

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2022-159169

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The phase 2 CARTITUDE-2 trial showed efficacy of cilta-cel in small groups at earlier disease stages, with response rates of 95 to 100% and an estimated duration of response of at least 12 months in 79 to 89% of patients who had a response.

    “The phase 2 CARTITUDE-2 trial showed the efficacy of cilta-cel in small groups (cohorts A and B) at earlier disease stages, with response rates of 95 to 100% and an estimated duration of response of at least 12 months in 79 to 89% of patients who had a response.”

    From Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. (2023) · cites this paper as [13]

  • After approximately 1.5 years of follow-up in CARTITUDE-2, 75 to 90% of patients remained progression-free.

    “After approximately 1.5 years of follow-up, 75 to 90% of patients remained progressionfree. 13,14”

    From Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. (2023) · cites this paper as [13]

  • The results add to the consistently strong efficacy that cilta-cel has shown throughout its clinical development, including in similar early lines of therapy in CARTITUDE-2, and confirm the efficacy observed in heavily pretreated patients in CARTITUDE-1.

    “The results also add to the consistently strong efficacy that cilta-cel has shown throughout its clinical development, including in similar, early lines of therapy populations in CARTITUDE-2, 13,14 and confirm the efficacy observed in heavily pretreated patients who received cilta-cel in CARTITUDE-1. 10,11”

    From Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. (2023) · cites this paper as [13]

Citations

Cited by

Sorted by citations

Metadata

Authors
Van De Donk, N. W., Agha, M., Cohen, A. D., Cohen, Y. C., Anguille, S., Kerre, T., Roeloffzen, W. W. H., Schecter, J. M., De Braganca, K. C., Jackson, C. C., Varsos, H., Mistry, P., Roccia, T., Xu, X., Li, K., Zudaire, E., Corsale, C., Akram, M., Geng, D., Pacaud, L., Sonneveld, P., & Zweegman, S.
Affiliations
  • Vrije Universiteit Amsterdam (NL)
  • UPMC Hillman Cancer Center (US)
  • University of Pennsylvania (US)
  • Tel Aviv University (IL)
  • University of Antwerp (BE)
  • Ghent University Hospital (BE)
  • University Medical Center Groningen (NL)
  • Janssen Research & Development (United States) (US)
  • 8Janssen Research & Development, Raritan, NJ
  • Janssen (United Kingdom) (GB)
  • 10Janssen Global Services, Raritan, NJ
  • 11Janssen Research & Development, Spring House, PA
  • Legend Biotech (United States) (US)
  • 13Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands
ORCID
Venue
Blood
Publisher
American Society of Hematology
Published
2022-11-15
Volume
140
Issue
Supplement 1
Pages
7536-7537
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood-2022-159169
OpenAlex
W4310103705
Cited by
25
References
0
Citations by year
2026: 1 · 2025: 5 · 2024: 4 · 2023: 15
FWCI
2.52
Type
journal article
Language
en
Open access
closed
Locations
  • Blood (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
cilta-cel, BCMA, CAR T-cell therapy, multiple myeloma, early recurrence, minimal residual disease negativity, autologous stem cell transplantation, cytokine release syndrome, movement disorders, pharmacokinetics, progression-free survival, overall survival, high-risk cytogenetics, treatment-naive patients

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review